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Abstract
Background: Utilization of lipid-lowering agents has been associated with improved long-term outcomes in acute
coronary syndrome (ACS) patients. However, updated data regarding local use and outcomes was lacking.
Methods: We retrospectively reviewed 696 hospitalized patients in the local ACS registry of Prince of Wales Hospital
during 1 January 2008 to 31 December 2009 with data retrieved using computerized clinical records of all patients.
Results: Among the 402 MI patients included, 104 (25.9 %) were not prescribed with statins at discharge. Percutaneous
coronary intervention (PCI) not performed or planned during hospitalization (OR: 0.324, p = 0.001) and latest lower
LDL-C level before discharge (OR: 0.221 for an increment of 1 mmol/L, p = 0.009) were significant independent
predictors of the absence of statin prescriptions at discharge. A significantly lower all-cause mortality rate (14.4 %
vs 51.7 %, p < 0.001), fewer total hospitalizations (p < 0.001) and fewer hospitalizations due to cardiovascular problems
(p < 0.001) were observed in patients discharged with statins. LDL-C goal attainment of < 2.6 mmol/L resulted in a
significant reduction in mortality (10.8 % vs 24.2 %, p = 0.001), but not for goal attainment of < 1.8 mmol/L. Significant
difference in survival existed only when LDL-C cut-off values were above 2.4 mmol/L.
Conclusions: This study revealed the under-utilization of statin therapy in eligible MI patients at discharge and
unsatisfactory percentages of LDL-C goal attainment, and also reassured the role of low LDL-C reduction to < 2.6 mmol/L
in the management of MI. However, the current study did not show that the lower LDL-C reduction improved survival of
ACS patients. Further research should be conducted to assess the necessity of aggressive LDL-C reduction to < 1.8 mmol/L
in local patients.
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Background
Encompassing unstable angina, non–ST-segment eleva-
tion myocardial infarction (NSTEMI) and ST-segment
elevation myocardial infarction (STEMI), acute coron-
ary syndrome (ACS) is a more severe type of coronary
heart disease (CHD) attributed to the rupture of ath-
erosclerotic plaque present in the coronary artery.
Serum cholesterol levels have been shown to continu-
ously correlate with CHD risk over a broad range of
cholesterol values [1–3], and elevated levels of low-
density lipoprotein cholesterol (LDL-C) are thought to
be a key determinant of CHD risk [4]. Utilization of
lipid-lowering agents, particularly 3-hydroxy-3-methyl-
glutaryl coenzyme A reductase inhibitors (statins), have
been associated with improved long-term outcomes in
ACS patients [5–9], and initiation of statins has been
recommended by international guidelines as a secon-
dary preventive strategy for recurrent ischemia and
mortality in ACS patients [10–14]. Current guidelines
recommend aggressive LDL-C reduction in patients
with established CHD [10–14]. The new ACC/AHA
adult treatment panel recommends more than 50 % re-
duction of the current LDL-C levels for high risk pa-
tients [13]. A previous local study conducted in the
early 2000’s revealed that 44 % of patients being put on
statins failed to achieve their cholesterol goals by a
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median follow-up period of 1.9 years [15]. Furthermore,
most clinical trials evaluating benefits of lipid-lowering
therapy were mainly carried out in Caucasian popula-
tions and had included few Chinese subjects. However,
differences in the pattern of lipid abnormalities and
their relative impact on CHD risk have been observed
among ethnic groups [16, 17]. Since both cholesterol
levels and CHD mortality are perceived to be lower in
Chinese population when compared to Western popu-
lations [18–20], the necessity for aggressive LDL-C
reduction in Chinese population remains uncertain.
Therefore, the current study primarily aimed to assess
the current prescribing pattern of lipid-lowering agents
and the percentage of LDL-C goal attainment in myo-
cardial infarction (MI) patients in local practice, and to
evaluate clinical outcomes of patients stratified by pre-
scription of statins and by LDL-C level attained after
discharge. Our study also aimed to examine the effect
of aggressive LDL-C reduction on survival in local MI
patients, and hence to evaluate its necessity.
Methods
This retrospective study utilized clinical data retrieved
from computerized clinical records of all MI patients
who were admitted to the Prince of Wales Hospital, a
teaching and major acute public hospital in Hong Kong,
during the period of 1 January 2008 to 31 December 2009.
The current study was conducted prior to the 2013 ACC/
AHA guidelines. Personal particulars of patients were ex-
tracted from the ACS registry, a local registry that records
all patients admitted to the hospital due to an ACS event.
Our study only included patients with ischemic symp-
toms or electrocardiographic changes accompanied by
an elevation of cardiac troponin T to > 0.10 ng/mL and
with a valid LDL-C levels. Relevant clinical information
was extracted up to the starting date of data collection,
18 December 2011. The protocol of this study was ap-
proved by the Joint CUHK-NTEC Clinical Research
Ethics Committee.
Statins were the primary lipid-lowering agents being
investigated in our study. Patients with combination
therapy of lipid-lowering agents or non-statin therapy
were excluded in the analysis. The agent prescribed and
its dose at various time points including the day before
admission, during hospitalization, at discharge and at
first follow-up were collected for analysis of prescribing
pattern in local clinical practice. For various statins be-
ing used, their daily doses were expressed as the
equivalent dose with respect to simvastatin 20 mg
[21, 22]. The dose equivalence was based on a 25–30 %
reduction in LDL-C [21].
Demographic information, smoking status, medical his-
tory and co-morbidities (heart failure – Patients with posi-
tive cardiac echocardiography findings and confirmed
diagnosis by cardiologists; hypertension – Patients with at
least 2 consecutive blood pressure measurements that ex-
ceed the target range according to the Joint National
Committee VII Report on hypertension; diabetes –
Patients with hemoglobin A1C greater than 7 %), presence
of ST-segment elevation in electrocardiogram, history of
interventional strategies performed or planned during
hospitalization, medication profiles and blood lipid pro-
files before and during index hospitalization, and serum
levels of alanine aminotransferase (ALT) and creatine kin-
ase (CK) during index hospitalization were recorded for
the analysis of patient characteristics.
Date of death, lipid profiles after index hospitalization,
number of hospitalizations after index hospitalization, and
history of revascularization after index hospitalization
were also collected for the analysis of patient outcomes.
Only unscheduled admissions were counted towards post-
discharge hospitalizations; scheduled workups, surgeries
and ward follow-ups were excluded. Post-discharge hospi-
talizations fell into the cardiac category if patients were
admitted due to cardiovascular events secondary to any
previous ACS episode (such as arrhythmia, shortness of
breath or fluid overload secondary to heart failure, cere-
brovascular accident (CVA), acute pulmonary edema, car-
diac chest pain and another ACS episode). Follow-up
period of an individual, as defined by the duration of post-
discharge survival period till the date of 18 December
2011, was also calculated.
Statistical method
The analyzing cohort was divided into 2 sub-groups
based on whether statins were prescribed at discharge
for the comparison of patient characteristics and out-
comes. LDL-C attainment analysis was done with similar
parameters by the stratification of the cohort with aver-
aged lipid values after 6 months post-discharge into
groups based on 2 different LDL-C goal attainments of
2.6 mmol/L and 1.8 mmol/L respectively. Hazard ratios
with 95 % confidence intervals were also presented. Logis-
tic regression analyses were performed to evaluate the in-
fluence of patient characteristics on prescription of statins
at discharge while Cox regression analysis was performed
to evaluate the influence of patient characteristics on mor-
tality; variables with p ≤ 0.20 in univariate analysis were
encompassed in the multivariate model.
Survival probabilities of the analyzed population were
illustrated using the Kaplan-Meier survival curves with
stratifications based on prescription of statins at discharge
and attainment of the two LDL-C goals (<1.8 mmol/L
and < 2.6 mmol/L). Survival probabilities of the whole
analyzed population stratified by various post-discharge
LDL-C cut-off values were also illustrated. Hazard ra-
tios (HRs) with 95 % confidence intervals (95 % CI)
were also presented.
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Continuous variables were analyzed using the Wilcoxon
rank sum test and expressed as medians with interquartile
ranges, while categorical variables were analyzed using the
Pearson chi-square test and expressed as frequencies with
percentages. Trend test was performed for number of hos-
pitalizations post-discharge and number of revasculariza-
tions. Difference in survival probabilities was analyzed by
the log-rank test. A p-value of < 0.05 was considered to be
statistically significant for the tests. All analyses were per-
formed using SPSS version 19.0.
Results
We retrospectively reviewed 696 patients with MI, and
402 of which were included in the analysis (Fig. 1). It is
important to note that 3 patients were excluded from
data analysis due to unsuitability for statins therapy be-
cause of elevation of liver function tests or elevation of
creatinine kinase with complain of myalgia because of
statin use at baseline. We did not detect any side effect
related to statins during the follow up period in our
study subjects who were on statin therapy. Among them,
191 (47.5 %) had a traceable record of a complete lipid
panel before admission, and 110 (57.6 %) of which had a
LDL-C ≥ 2.6 mmol/L. Not all patients had at least one
LDL-C check-ups during hospitalization, and only 340
(84.6 %) had so (Table 1). Although a total of 209 (61.5 %)
patients had LDL-C ≥ 2.6 mmol/L during hospitalization,
30 (14.4 %) of them were not prescribed any statins at dis-
charge (Table 1). By taking LDL-C < 1.8 mmol/L as the
more aggressive goal for MI patients, 307 (90.3 %) patients
were not at goal before discharge, and 63 (20.5 %) of which
did not receive any statin therapy at discharge. Excluding
patients died within the 6-month period post-discharge
(n = 22), a total of 346 (91.1 %) patients had at least one
lipid panel conducted 6 months after discharge (Table 1).
The use of statins at discharge was significantly associated with
Fig. 1 Number of patients being prescribed with statins at various time points. *The dose listed were the equivalent daily dose with respect
to simvastatin
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lower LDL-C level 6-month post-discharge (p<0.001), although
there were more patients with LDL between 1.8 mmol/L and
2.6 mmol/L than less than 1.8 mmol/L.
Patients were stratified into statin and non-statin
groups for investigation of patient characteristics associ-
ated with the absence of statin prescription at discharge.
Among those patients discharged with statins (n = 298),
majority of our patients were on monotherapy lipid low-
ering agent (mainly statin) at discharge. There were 268
(90 %) patients who were prescribed with simvastatin,
Rosuvastatin, atorvastatin and lovastatin were prescribed
in 24 (8.1 %), 5 (1.7 %) and 1 (0.3 %) patients respect-
ively. We excluded patients with combination therapy of
lipid-lowering agents or non-statin therapy. There were
6 patients being excluded: 3 patients on monotherapy
gemfibrozil 1200 mg/day, 1 patient with gemfibrozil
600 mg/day plus simvastatin 40 mg, 2 patients with eze-
timibe 10 mg/day plus atorvastatin 80 mg. Variables with
p ≤ 0.20 in univariate analysis were encompassed in the
multivariate model (Table 2). The multivariate Cox regres-
sion analysis revealed that PCI not performed or planned
during hospitalization (OR: 0.324, p = 0.001) and latest
lower LDL-C level before discharge (OR: 0.221 for an in-
crement of 1 mmol/L, p = 0.009) were significant inde-
pendent predictors for the absence of statin prescription
(Table 2). In other words, patients without PCI performed
or planned during hospitalization and with low LDL-C
level before discharge were less likely to be prescribed
with statins.
More patients prescribed with statins at discharge
achieved a lower LDL-C level 6-month post-discharge
(p < 0.001). In a medium follow-up period of 1022
(752.5–1236.0) days in all patients, a significantly lower
all-cause mortality rate was observed in patients dis-
charged with statins (14.4 % vs 51.7 %, p < 0.001). Further-
more, patients discharged with statins were found to have
a lower number of total hospitalizations and hospitaliza-
tions due to cardiovascular problems secondary to any
previous ACS episode after index hospitalization. Patients
with statins who had at least one hospitalization due to
cardiovascular disease were 116 (38.9 %) versus 58
(55.8 %) in the non-statin group [p < 0.001]. Nevertheless,
percentages of patients requiring revascularizations in-
cluding PCI (statin group: n = 30 [10.1 %]; non-statin
group: n = 5 [4.8 %]; p = 0.133) and CABG (statin group:
n = 5 [1.7 %]; non-statin group: n = 2 [1.9 %]; p = 0.869)
were similar between the statin and non-statin cohorts.
Kaplan-Meier curves illustrating survival of patients
discharged with or without statins also revealed that
prescription of statins at discharge was significantly as-
sociated with reduction of mortality (HR: 0.285, 95 %
CI: 0.188–0.433, p < 0.001) (Fig. 2). We found that there
were statistically significant differences between the sta-
tin group versus non-statin group in terms of baseline
characteristics. The patients who did not take statins at
discharge were older (average age: 70 years old versus
79 years old; p < 0.001), with more previous ischemic
heart disease/acute coronary syndrome (19.8 % versus
32.7 %; p = 0.007), cerebrovascular accident (8.4 % ver-
sus 14.4 %; p = 0.077), heart failure (9.4 % versus
30.8 %; p < 0.001) and poorer creatinine kinase levels
(3.0 % versus 8.9 %; p = 0.023) as well as liver function
(0.7 % versus 3.9 %; p = 0.041). Therefore, although the
patients who did not take statins may have achieved the
LDL-C goal, they had poorer clinical outcomes due to
other co-existing conditions.
Patient characteristics of the cohort of 346 subjects
with at least one lipid panel checked 6 months post-
discharge were evaluated. Several patient characteristics
were associated with a higher probability of achieving a
desirable LDL-C 6 months after discharge. When LDL-
C < 2.6 mmol/L was taken as the desirable level, these
characteristics included being prescribed with statins at
discharge (p < 0.001) and a lower LDL-C (p = 0.028) and
TG (p = 0.043) before discharge. However, if the more
stringent LDL-C goal of 1.8 mmol/L was taken into con-
sideration, characteristics associated with higher prob-
ability of achieving a desirable 6-month post-discharge
Table 1 LDL-C levels and statin utilization of patients at various time points
LDL-C≤ 1.8 1.8 < LDL-C ≤2.6 LDL-C > 2.6 P value
Before admission Statin group (n = 130)a 15 (11.5 %) 37 (28.5 %) 78 (60.0 %) 0.203
Non-statin group (n = 61)a 13 (21.3 %) 16 (26.2 %) 32 (52.5 %)
Total (n = 191) 28 (14.7 %) 53 (27.7 %) 110 (57.6 %) /
Latest during hospitalization Statin group (n = 269)a 25 (9.3 %) 65 (24.2 %) 179 (66.5 %) <0.001
Non-statin group (n = 71)a 8 (11.3 %) 33 (46.5 %) 30 (42.3 %)
Total (n = 340) 33 (9.7 %) 98 (28.8 %) 209 (61.%) /
Half-year post-discharge Statin group (n = 272)a 98 (36.0 %) 115 (42.3 %) 59 (21.7 %) <0.001
Non-statin group (n = 61)a 15 (20.3 %) 23 (31.1 %) 36 (48.6 %)
Total (n = 191) 113 (32.7 %) 138 (39.9 %) 95 (27.5 %) /
aPatients were stratified according to prescription of statins at discharge
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LDL-C level included a higher age (p = 0.040), being not
an active smoker (p = 0.002), being prescribed with sta-
tins at discharge (p = 0.010) and a lower LDL-C before
discharge (p < 0.001).
With a LDL-C < 2.6 mmol/L attained 6 months after dis-
charge, a lower all-cause mortality was observed (10.8 % vs
24.2 %, p = 0.001). However, this difference became insig-
nificant if the more stringent goal of 1.8 mmol/L was used
(13.3 % vs 15.0 %, p = 0.947). Moreover, no significant asso-
ciation could be noted between attainment of LDL-C goal
of either < 2.6 mmol/L or < 1.8 mmol/L and number of
hospitalizations as well as revascularization. Survival of
patients by attainment of LDL-C goals of < 2.6 mmol/L
and < 1.8 mmol/L also revealed that attainment of LDL-
C < 2.6 mmol/L was associated with reduction of mortality
significantly (HR: 0.413, 95 % CI: 0.237–0.720, p = 0.002),
but not attainment of LDL-C < 1.8 mmol/L (HR: 0.891,
95 % CI: 0.487–1.633, p = 0.710).
The multivariate Cox regression analysis encompass-
ing variables with p ≤0.20 on univariate Cox regression
analysis revealed that age at discharge (HR: 1.066 for an
1-year increment, p = 0.001), co-morbidity of heart failure
(HR: 2.859, p = 0.002), STEMI at index hospitalization (HR:
0.318, p = 0.002) and first LDL-C level 6 months after dis-
charge (HR: 1.824, p = 0.003 for an increment of 1 mmol/L)
were significant predictors of prognosis (Table 3). Signifi-
cant association was demonstrated between attainment of
LDL-C goal of < 2.6 mmol/L and reduction in mortality,
but not for attainment of LDL-C goal of < 1.8 mmol/L.
Stratifications of all patients for mortality analyses
based on different LDL-C cut-off values produced sur-
vival curves with different significant levels (Fig. 3). A
decrease in the survival difference between patients
above and below cut-off values was observed when the
LDL-C cut-off value became more aggressive from
2.6 mmol/L (p = 0.001) to 2.2 mmol/L (p = 0.408). Taking
LDL-C level of 2.4 mmol/L as the cut-off, patients
attaining LDL-C < 2.4 mmol/L at 6-month post-discharge
had a significantly better survival than those did not (p =
0.028). However, this difference became insignificant when
the LDL-C level of 2.3 mmol/L was taken as the cut-off
(p = 0.187).
Discussion
Lipid-lowering therapy including statin therapy is an im-
portant ACS management strategy to prevent complica-
tions secondary to ACS and all patients with baseline
LDL-C not at goal should have lipid-lowering therapy
for LDL-C goal attainment [10–14]. Our study, however,
revealed the under-utilization of statin therapy in eligible
STEMI and NSTEMI patients without any contraindica-
tion to statins and failure in LDL-C goal attainment in
some patients.
A common approach for enhancing goal achievement
involves the use of higher equipotency doses of statins
such as titrating up simvastatin doses or utilizing statins
with higher equipotency than simvastatin, the use of
add-on agents such as ezetimibe to statins [23–25] and
to establish the role of pharmacists in lipid attainment
[26, 27]. A prospective controlled study showed that pa-
tient compliance and ATP III LDL-C goal attainment
could be significantly enhanced compared with control
group after individualized counseling and follow-up by
pharmacists [26].
Prescription of statins was significantly associated with
lower mortality (p < 0.001), which is in line with other
studies [5–9]. Significantly much lower cardiac and all-
cause re-hospitalizations were also observed with the
use of statins at discharge, but not for revascularization.
Patients with statins in this study had significantly higher
percentages of in-hospitalization PCI (done or planned),
suggesting more severe forms of ACS and hence, more
Fig. 2 Kaplan-Meier survival function by prescription of statins at discharge.Note: All-cause mortality = 43/298 (14.4%) in statin group versus
46/104 (51.7%) in non-statin group
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aggressive treatments such as revascularization may be
preferred over medication treatment alone in case of re-
current ACS. Willingness and appropriateness (such as
age) of patients to undergo revascularization were also
potential confounders.
Several patient characteristics have been identified to
be associated with poorer prognosis in our study, which
included older age, co-morbidity of heart failure, pres-
entation of NSTEMI at index hospitalization and high
LDL-C level at the first lipid panel at least 6-month
after discharge. The presence of heart failure may re-
flect that myocardial cells are more severely damaged,
which probably explains its association with higher
mortality. Since poor control of blood pressure and
blood glucose are significant risk factors of heart failure
[28, 29], modifications of diet and medications targeting
better control may be beneficial in delaying disease pro-
gression and thus reducing mortality. The association
between high post-discharge LDL-C level and poor
prognosis observed has illustrated that attainment of
LDL-C goals is a more important predictor of death,
but not prescription of statins. This has signified the
importance of regular monitoring of blood lipid levels,
with intensification of lipid-lowering therapy in patients
not achieving desirable LDL-C levels. The association
of non–ST-segment elevation with poorer prognosis
Table 2 Predictors of the absence of statin prescription in univariate and multiple logistic regression
Variable Odds ratio 95 % CI p-value
Univariate Logistic Regression Analysis
Male sex 0.492 0.310–0.780 0.003
Age at discharge 1.059 1.036–1.083 <0.001
Active smoking status 0.642 0.366–1.124 0.121
Past medical history of IHD or ACS 1.968 1.195–3.241 0.008
Past medical history of CVA 1.840 0.929–3.645 0.080
Co-morbidity of hypertension 1.061 0.668–1.685 0.802
Co-morbidity of heart failure 4.286 2.424–7.578 <0.001
Co-morbidity of diabetes mellitus 1.459 0.930–2.289 0.101
STEMI at index hospitalization 0.616 0.389–0.975 0.038
PCI done or planned during index hospitalization 0.191 0.114–0.321 <0.001
CABG done or planned during index hospitalization 0.418 0.142–1.229 0.113
Latest TG level before discharge 0.682 0.485–0.960 0.028
Latest HDL-C level before discharge 1.270 0.590–2.736 0.541
Latest LDL-C level before discharge 0.551 0.398–0.763 <0.001
Latest serum ALT level before discharge > 3 × ULN 5.919 1.068–32.812 0.042
Latest serum CK level before discharge > 2 × ULN 3.141 1.211–8.419 0.019
Multiple Logistic Regression Analysis
Male sex 0.829 0.429–1.604 0.578
Age at discharge 1.012 0.983–1.041 0.426
Active smoking status 1.337 0.626–2.857 0.453
Past medical history of IHD or ACS 1.200 0.569–2.531 0.633
Past medical history of CVA 0.643 0.230–1.794 0.399
Co-morbidity of heart failure 1.750 0.767–3.991 0.184
Co-morbidity of diabetes mellitus 1.258 0.686–2.309 0.458
STEMI at index hospitalization 0.753 0.417–1.358 0.346
PCI done or planned during index hospitalization 0.324 0.167–0.629 0.001
CABG done or planned during index hospitalization 0.458 0.162–1.824 0.324
Latest TG level before discharge 0.009 0.601–1.258 0.458
Latest LDL-C level before discharge 0.221 0.423–0.885 0.009
Latest serum ALT level before discharge > 3 × ULN 0.197 0.472–25.654 0.221
Latest serum CK level before discharge > 2 × ULN 0.950 0.660–7.462 0.197
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seems to be surprising, as STEMI has been traditionally
classified as the most severe manifestation of the ACS
spectrum [12–14]. However, our finding is in fact con-
sistent with previous retrospectively study that NSTEMI
patients have unadjusted mortality rates higher than pa-
tients with STEMI [30–32]. Allen and his colleagues
have shown that ST-elevation would be associated with
the highest risk when potential confounders in baseline
characteristics and treatment were adjusted, and indi-
cated that NSTEMI patients are less likely to receive
standard therapies because STEMI can be diagnosed
immediately on electrocardiogram and has historically
been viewed as the most concerning diagnosis in the
spectrum of ACS [30].
With a significantly better survival observed in patients
attaining levels of LDL-C below 2.6 mmol/L but not below
1.8 mmol/L, we have further investigated the survival
probability of patients attaining different LDL-C levels
post-discharge. Contrasting to current evidence that sug-
gest the reduction of LDL-C to < 1.8 mmol/L in high risk
patients [11], our results indicated that patients attaining
levels between 1.8 mmol/L and 2.6 mmol/L had a better
survival than those with levels below 1.8 mmol/L in our
study. Given the differences may exist in the pattern of
lipid abnormalities and their relative impact on CHD risk
among ethnic groups, our results have created controversy
on the necessity of aggressive reduction of LDL-C to
below 1.8 mmol/L in local Chinese population. When
more survival curves were plotted with stratification of
the study population by various LDL-C cut-off values
between 2.6 mmol/L and 1.8 mmol/L, a reduction in
survival difference between patients below and above
the cut-off value was observed as more aggressive LDL-
C cut-off values were taken. A significant better sur-
vival was seen in patients attaining LDL-C < 2.4 mmol/
L (when compared to those did not), but not in patients
attaining LDL-C < 2.3 mmol/L (when compared to
those did not). Therefore, our results suggested that the
LDL-C goal in local population may be < 2.4 mmol/L, if
a difference in threshold should exist among ethnic
groups. The current 2013 ACC/AHA cholesterol guide-
lines recommended high-risk cardiovascular patients to
Fig. 3 Kaplan-Meier survival function of all patients stratified by new LDL-C cut-off values
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attain 50 % LDL-C reduction11. In our current project,
we observed that over 42.4 % of patients had a baseline
LDL-C level of < 2.6 mmol/L before admission. There-
fore, the target goal will be < 1.3 mmol/L according to
the 2013 ACC/AHA cholesterol guidelines. According
to our current study, the lower LDL-C reduction did
not translate into better clinical survival. The cost of
management may also increase due to the use of high-
potency statin such as rosuvastatin that may pose eco-
nomic concerns for healthcare providers.
Table 3 Predictors of mortality in univariate Cox proportional hazards regression model and multivariate Cox regression analysis
Variable Hazard ratio 95 % CI p-value
Univariate Cox proportional hazards regression model of mortality
Male sex 0.525 0.346–0.796 0.002
Age at discharge 1.069 1.045–1.092 <0.001
Active smoking status 0.511 0.284–0.920 0.025
Past medical history of IHD or ACS 1.827 1.177–2.836 0.007
Past medical history of CVA 2.755 1.688–4.498 <0.001
Co-morbidity of hypertension 1.601 1.008–2.542 0.046
Co-morbidity of heart failure 4.266 2.770–6.570 <0.001
Co-morbidity of diabetes mellitus 1.786 1.174–2.715 0.007
STEMI at index hospitalization 0.345 0.213–0.560 <0.001
PCI done or planned during index hospitalization 0.185 0.108–0.318 <0.001
CABG done or planned during index hospitalization 0.609 0.223–1.660 0.332
Latest TG level before discharge 0.842 0.617–1.149 0.279
Latest HDL-C level before discharge 0.674 0.298–1.521 0.342
Latest LDL-C level before discharge 0.873 0.649–1.175 0.370
Prescription of statins at discharge 0.285 0.188–0.433 <0.001
Latest CK level before discharge > 2 × ULN 1.659 0.724–3.803 0.231
Latest serum ALT level before discharge > 3 × ULN 6.491 2.371–17.770 <0.001
First TG level 6 months after discharge 0.740 0.478–1.145 0.177
First HDL-C level 6 months after discharge 0.875 0.402–1.905 0.737
First LDL-C level 6 months after discharge 1.685 1.230–2.308 0.001
Number of in-patient hospitalization due to cardiac reasons 1.076 1.034–1.120 <0.001
Predictors of mortality in multivariate Cox regression analysis
Male sex 0.936 0.487–1.801 0.843
Age at discharge 1.066 1.027–1.107 0.001
Active smoking status 1.602 0.671–3.825 0.289
Past medical history of IHD or ACS 0.493 0.237–1.023 0.057
Past medical history of CVA 1.804 0.866–3.758 0.115
Co-morbidity of hypertension 0.765 0.364–1.608 0.480
Co-morbidity of heart failure 2.859 1.448–5.646 0.002
Co-morbidity of diabetes mellitus 1.217 0.632–2.342 0.556
STEMI at index hospitalization 0.318 0.157–0.645 0.002
PCI done or planned during index hospitalization 0.468 0.203–1.075 0.074
Prescription of statins at discharge 0.833 0.416–1.664 0.604
Latest serum ALT level before discharge > 3 × ULN 0.961 0.113–8.116 0.971
First TG level 6 months after discharge 0.695 0.384–1.260 0.231
First LDL-C level 6 months after discharge 1.824 1.233–2.697 0.003
Number of in-patient hospitalization due to cardiac reasons 1.010 0.928–1.100 0.814
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Several limitations exist in our current study. Study
population was restricted to patients admitted to a major
teaching hospital in Hong Kong, in which clinical ex-
perience of physicians there may be different from that
of other hospitals in Hong Kong. Therefore, the results
obtained may not truly reflect the actual prescribing
practice in Hong Kong. The multivariate Cox propor-
tional hazards regression model of mortality was unable
to include all variables that may possibly be associated
with all-cause mortality observed during the follow-up
duration, such as co-morbidities of fatal diseases and
prescription of other evidence-based medicines in the
management of MI. Last but not least, being a retro-
spective study analyzing computerized clinical records,
the current study is unable to identify any factors that
were not documented in computer records but may po-
tentially influence the prescription of statins. More im-
portantly, the possible existence of confounders in our
study may have potentially caused the insignificant dif-
ference observed in survival between patients above and
below LDL-C cut-off values when LDL-C levels below
2.3 mmol/L were taken as the cut-off values. In addition,
we did not adjust for the patients’ characteristics fort he
Kaplan Meier analysis due to small sample size. Further
research, preferably randomized controlled trials, should
be conducted to confirm our findings regarding the ne-
cessity of aggressive LDL-C reduction in local Chinese
population.
Conclusions
This study revealed the under-utilization of statin ther-
apy in eligible MI patients at discharge, particularly in
patients without undergoing PCI and with low LDL-C
levels during hospitalization. Unsatisfactory LDL-C goal
attainment in MI patients was observed. This study also
reassured the role of LDL-C reduction to < 2.6 mmol/L
in the management of MI. However, the current study
did not show that the lower LDL-C reduction improved
survival of ACS patients. Further research should be
conducted to assess the necessity of aggressive LDL-C
reduction to < 1.8 mmol/L in local patients.
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